The country’s Medicines and Healthcare products Regulatory Agency’s (MHRA) Yellow Card scheme, the UK’s official system for ...

See how GLP-1 drugs reduce heart and kidney complications in MGUS and diabetes—explore the clinical evidence. Keep reading!

A current weight-loss and diabetes drug has become a surprise candidate for migraine treatment, with a new pilot study ...

GLP-1 receptor agonists may increase the risk of several autoimmune diseases in adults with type 2 diabetes, according to ...

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

GLP-1 drugs like Ozempic® and Zepbound® have gained significant attention for treating both diabetes and assisting with weight loss.

The UK's medicines regulator has launched a study to investigate the impact of these drugs following reports of people dying ...

SGLT2 inhibitors, compared with GLP-1 RAs, were associated with lower risks for osteoarthritis and joint replacement surgery among patients with T2D.

People undergoing metabolic and bariatric surgery are less likely to develop psychiatric disorders than those treated with GLP-1 RAs.